32 patents
Utility
Cyclobenzaprine Treatment for Alcohol Use Disorder
11 Jan 24
The present disclosure provides a method for treating alcohol use disorder (AUD) and associated symptoms to a subject in need thereof by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Seth Lederman, Greg M. Sullivan
Filed: 19 Nov 21
Utility
CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-CoV-2 INFECTION (PASC)
28 Dec 23
The present disclosure provides methods for treating Post-Acute Sequelae of Severe Acute Respiratory Syndrome (SARS)-CoV-2 infection (PASC) or one or more symptoms associated with said PASC, comprising administering to a subject in need or at risk thereof a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Seth Lederman
Filed: 21 Jun 23
Utility
Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
12 Dec 23
The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
Marino Nebuloni, Patrizia Colombo
Filed: 28 Oct 20
Utility
Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
28 Nov 23
Compositions comprising cyclobenzaprine, and methods for the treatment or prevention of agitation, psychosis and/or cognitive decline and associated symptoms thereof in dementia and other neurodegenerative conditions.
Herbert W. Harris, Seth Lederman
Filed: 11 Dec 18
Utility
Analogs of Cyclobenzaprine and Amitryptilene
18 May 23
The present invention relates to cyclobenzaprine analogs and amitriptyline analogs, including deuterated forms useful for treatment or prevention of symptoms associated with post-traumatic stress disorder.
Seth Lederman, Darryl Rideout, Greg Sullivan
Filed: 5 Dec 22
Utility
Radio-protective and Chemo-protective Substituted Thiols
4 May 23
Philip S. Schein, Darryl C. Rideout
Filed: 21 Nov 22
Utility
Radio-protective and chemo-protective substituted thiols
31 Jan 23
Philip S. Schein, Darryl C. Rideout
Filed: 7 May 21
Utility
Synthetic Chimeric Poxviruses
5 Jan 23
The invention relates, in general, to synthetic chimeric poxviruses, compositions comprising such viruses, and the development and use of systems and methods for producing such synthetic chimeric poxviruses.
David Evans, Ryan Noyce, Seth Lederman
Filed: 27 May 22
Utility
Analogs of cyclobenzaprine and amitriptyline
6 Dec 22
The present invention relates to cyclobenzaprine analogs and amitriptyline analogs, including deuterated forms useful for treatment or prevention of symptoms associated with post-traumatic stress disorder.
Seth Lederman, Darryl Rideout, Greg Sullivan
Filed: 13 Jul 18
Utility
ANTI-CD154 Antibodies and Uses Thereof
1 Dec 22
This disclosure relates to anti-human CD154 antibodies with modified effector function.
Seth Lederman
Filed: 1 Jul 20
Utility
Modified TFF2 Polypeptides
8 Sep 22
Described herein are modified TFF2 polypeptides, compositions comprising these polypeptides and their use to treat cancer and inflammation.
Seth Lederman, Bruce Daugherty
Filed: 27 Aug 20
Utility
Magnesium-containing oxytocin formulations and methods of use
19 Jul 22
Disclosed are magnesium-containing oxytocin peptide formulations or compositions comprising an oxytocin peptide and a magnesium salt that produces synergistic analgesia when used in treating pain.
David C. Yeomans, Dean Carson, Ramachandran Thirucote
Filed: 7 Jan 16
Utility
Inhibitors of CD40-CD154 Binding
16 Jun 22
Disclosed herein are compounds including pharmaceutically acceptable salts, esters, prodrugs, hydrates and tautomers thereof which modulate the interactions of CD-40-CD40L.
Darryl RIDEOUT, Seth LEDERMAN
Filed: 13 Apr 20
Utility
Randomization Honoring Methods to Assess the Significance of Interventions on Outcomes In Disorders
28 Apr 22
Systems and methods for an analysis of clinical trial data using randomization tests that honors the randomized design of the clinical trial are provided herein.
Seth Lederman, Philip B. Stark, Ben Vaughn
Filed: 22 Oct 21
Utility
Methods of Treating Acute Stress Disorder and Posttraumatic Stress Disorder
21 Apr 22
This invention relates to methods of treating posttraumatic stress disorder and acute stress disorder using pharmaceutical compositions comprising cyclobenzaprine, amitriptyline, or pharmaceutically acceptable salts thereof.
Perry Scott Peters, Gregory M. Sullivan, Ernest Mario, Herbert Harris, Seth Lederman
Filed: 20 Aug 19
Utility
Skin-based Testing for Detection of Cell-mediated Immune Responses to SARS-COV-2
20 Jan 22
The present disclosure provides methods for detecting cell-mediated immunity to SARS-CoV-2 in a subject, methods for detecting a cell-mediated immune response against SARS-CoV-2 in a subject and methods for determining if a vaccine against SARS-CoV-2 elicits a cell-mediated immune response in a subject, comprising administering to the skin of the subject one or more peptides.
Seth Lederman, Siobhan J. Fogarty
Filed: 16 Jul 21
Utility
Radio-and Chemo-protective Compounds
16 Dec 21
The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methylamino)methyl)propane-1-thiol.
Philip S. Schein, Darryl C. Rideout
Filed: 7 May 21
Utility
Cyclobenzaprine Treatment for Sexual Dysfunction
14 Oct 21
The present disclosure provides a pharmaceutical composition comprising therapeutically effective amounts of cyclobenzaprine and one or more agents, and methods of treating and/or preventing sexual dysfunction.
Megan Elizabeth Parmenter, Gregory M. Sullivan
Filed: 8 Apr 21
Utility
RECOMBINANT POXVIRUS BASED VACCINE AGAINST SARS-CoV-2 VIRUS
26 Aug 21
The invention relates in various aspects to a recombinant poxvirus comprising a nucleic acid encoding a SARS-CoV-2 virus protein, methods for producing such viruses and the use of such viruses.
Seth Lederman, Scott J. Goebel, David Evans, Ryan Noyce
Filed: 26 Feb 21
Utility
Stem Cells Comprising Synthetic Chimeric Vaccinia Virus and Methods of Using Them
5 Aug 21
The invention relates in various aspects to stem cells comprising a synthetic chimeric poxvirus (scPV), which can be used for the treatment of cancer or other infectious diseases.
Seth Lederman
Filed: 2 May 19